DDR1 and neoplasm: Efforts are underway to develop more selective DDR1 inhibitors and monoclonal antibodies, such as DDR1-IN-1 (23), 7rh (24) and 48B3 (41), which have demonstrated promise in preclinical studies by inhibiting tumor growth.